You are here

obesity

Pfizer advances diabetes, obesity drug hopeful into mid-stage testing

BioPharma Dive

Wed, 12/21/22 - 12:34 pm

Lilly and Pfizer fight for new territory in obesity and diabetes

EP Vantage

Thu, 12/15/22 - 10:46 am

‘Diabesity’ marketing set to swell as Novo preps relaunch of weight-loss drug

Medical Marketing and Media

Wed, 12/14/22 - 10:36 am

pharma marketing

Eli Lilly tightens access to diabetes drug, frustrating some people with obesity

Stat

Wed, 12/7/22 - 10:08 am

type 2 diabetes

Lilly gearing up for 'substantial expansion' of diabetes med manufacturing by 2025

Fierce Pharma

Tue, 12/6/22 - 09:00 pm

type 2 diabetes

drug manufacturing

Boston Scientific's struggle with obesity

EP Vantage

Mon, 12/5/22 - 10:44 am

Boston Scientific

Apollo Endosurgery

Amgen to push latecomer obesity drug into midstage testing

Pharmaphorum

Sun, 12/4/22 - 01:26 pm

clinical trials

Looming obesity drug rivalry not a concern for Novo CEO

Reuters

Wed, 11/16/22 - 10:42 am

Early data hint at benefit for Amgen’s obesity drug

BioPharma Dive

Wed, 11/9/22 - 10:32 am

Why Amgen Is Up More Than 6% Today

Motley Fool

Tue, 10/11/22 - 04:05 pm

Eli Lilly tasks Nimbus with hitting a 'high-value' target for diabetes, obesity

Endpoints

Tue, 10/11/22 - 10:33 am

Lilly's tirzepatide slides into FDA fast lane for obesity, turning up heat on Novo Nordisk's Wegovy

Fierce Pharma

Thu, 10/6/22 - 10:59 am

With Lilly's Mounjaro set for stardom, an Alzheimer's win would be 'icing on the cake': analysts

Fierce Pharma

Fri, 09/23/22 - 10:48 am

type 2 diabetes

Alzheimer's disease

Weight loss player gets attention of RA Capital, walks away with $132M to keep pursuing big targets

Endpoints

Thu, 09/22/22 - 10:16 am

Rivus Pharmaceuticals

Targeting Novo Nordisk in China's obesity market with a unique proposition, LeaderMed eyes US IPO

Fierce Biotech

Fri, 09/2/22 - 12:32 pm

A pharmaceutical jack of all trades? Novo CEO touts semaglutide's potential in NASH, Alzheimer's and its hot start in obesity

Fierce Pharma

Mon, 08/29/22 - 10:40 am

Alzheimer's disease

Amid Wegovy's supply woes, Novo Nordisk sees surging demand for its original obesity drug Saxenda

Fierce Pharma

Thu, 08/4/22 - 11:05 am

drug manufacturing

Novo Nordisk, Eli Lilly poised to divvy up obesity market that could be worth $50B in 2030: analysts

Fierce Pharma

Sun, 07/17/22 - 11:07 pm

A decade after its first approval, FDA expands weight loss pill's label for use in adolescents

Endpoints

Tue, 06/28/22 - 10:44 am

Innovent catching up with Lilly, Novo Nordisk thanks to phase 2 obesity data

Fierce Biotech

Wed, 06/8/22 - 10:34 am

clinical trials

Pages